These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36931117)

  • 1. Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.
    Jia R; Zhang J; Shi F; Bonomini A; Lucca C; Bertagnin C; Zhang J; Liu C; Jia H; Jiang Y; Ma X; Loregian A; Huang B; Zhan P; Liu X
    Eur J Med Chem; 2023 Apr; 252():115275. PubMed ID: 36931117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Boron-Containing
    Jia R; Zhang J; Zhang J; Bertagnin C; Bonomini A; Guizzo L; Gao Z; Ji X; Li Z; Liu C; Ju H; Ma X; Loregian A; Huang B; Zhan P; Liu X
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors
    Ju H; Hou L; Zhao F; Zhang Y; Jia R; Guizzo L; Bonomini A; Zhang J; Gao Z; Liang R; Bertagnin C; Kong X; Ma X; Kang D; Loregian A; Huang B; Liu X; Zhan P
    J Med Chem; 2022 Sep; 65(17):11550-11573. PubMed ID: 35939763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.
    Ju H; Zhang J; Sun Z; Huang Z; Qi W; Huang B; Zhan P; Liu X
    Eur J Med Chem; 2018 Feb; 146():220-231. PubMed ID: 29407952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
    Jia R; Zhang J; Bertagnin C; Cherukupalli S; Ai W; Ding X; Li Z; Zhang J; Ju H; Ma X; Loregian A; Huang B; Zhan P; Liu X
    Eur J Med Chem; 2021 Feb; 212():113097. PubMed ID: 33385836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel
    Zhang J; Liu C; Jia R; Zhang X; Zhang J; Bertagnin C; Bonomini A; Guizzo L; Jiang Y; Jia H; Jia S; Ma X; Loregian A; Huang B; Zhan P; Liu X
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2277135. PubMed ID: 37955306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
    Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W
    J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel polyheterocyclic neuraminidase inhibitors with 1,3,4-oxadiazole thioetheramide as core backbone.
    Shang LL; Zhong ZJ; Cheng LP
    Eur J Med Chem; 2024 Apr; 269():116305. PubMed ID: 38518525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
    Ai W; Zhang J; Zalloum WA; Jia R; Cherukupalli S; Ding X; Sun Z; Sun L; Jiang X; Ma X; Li Z; Wang D; Huang B; Zhan P; Liu X
    Eur J Med Chem; 2020 Apr; 191():112147. PubMed ID: 32092589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
    Zhang J; Murugan NA; Tian Y; Bertagnin C; Fang Z; Kang D; Kong X; Jia H; Sun Z; Jia R; Gao P; Poongavanam V; Loregian A; Xu W; Ma X; Ding X; Huang B; Zhan P; Liu X
    J Med Chem; 2018 Nov; 61(22):9976-9999. PubMed ID: 30365885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.
    Li Z; Meng Y; Xu S; Shen W; Meng Z; Wang Z; Ding G; Huang W; Xiao W; Xu J
    Bioorg Med Chem; 2017 May; 25(10):2772-2781. PubMed ID: 28385598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of NH
    Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y
    Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
    Singh A; Soliman ME
    Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors.
    Jia R; Zhang J; Ai W; Ding X; Desta S; Sun L; Sun Z; Ma X; Li Z; Wang D; Huang B; Zhan P; Liu X
    Eur J Med Chem; 2019 Sep; 178():64-80. PubMed ID: 31176096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of C5-NH
    Ju H; Murugan NA; Hou L; Li P; Guizzo L; Zhang Y; Bertagnin C; Kong X; Kang D; Jia R; Ma X; Du R; Poongavanam V; Loregian A; Huang B; Liu X; Zhan P
    J Med Chem; 2021 Dec; 64(24):17992-18009. PubMed ID: 34735766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
    Zhang H; Wang K; Zhu H; Zhao X; Zhao H; Lei Z; Chen B; Yang F; Liu K; Zhang K; Wang J; Tian Y
    Eur J Med Chem; 2020 Aug; 200():112423. PubMed ID: 32512482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.
    Zhao H; Jiang S; Ye Z; Zhu H; Hu B; Meng P; Hu Y; Zhang H; Wang K; Wang J; Tian Y
    Eur J Med Chem; 2021 Oct; 221():113567. PubMed ID: 34082224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
    Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
    Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
    Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
    J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
    Zhang J; Poongavanam V; Kang D; Bertagnin C; Lu H; Kong X; Ju H; Lu X; Gao P; Tian Y; Jia H; Desta S; Ding X; Sun L; Fang Z; Huang B; Liang X; Jia R; Ma X; Xu W; Murugan NA; Loregian A; Huang B; Zhan P; Liu X
    J Med Chem; 2018 Jul; 61(14):6379-6397. PubMed ID: 29965752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.